Weyerhaeuser Reinitiates Dividend

While reporting higher third-quarter earnings and sales, Weyerhaeuser Co. (WY) on Friday said it is reinitiating a quarterly dividend that was temporarily suspended in May amid the coronavirus pandemic.

For the fourth quarter 2020, the board of directors has declared a quarterly base cash dividend of $0.17 per share.

Further, the private owner of timberlands is also implementing a new dividend framework to enhance its ability to return cash to shareholders across a variety of market conditions.

The new dividend framework includes two components, such as sustainable quarterly base cash dividend and variable supplemental dividend. The company expects to supplement its quarterly base dividend with an additional return of cash, as appropriate, to achieve a targeted total annual return to shareholders of 75 to 80 percent of annual Adjusted Funds Available for Distribution.

The company noted that demand for housing and wood products has proven resilient over the past several months.

Looking ahead for the fourth quarter, timberlands segment expects sequentially higher earnings and Adjusted EBITDA in the fourth quarter.

Devin Stockfish, president and chief executive officer, said, "Entering the fourth quarter, Weyerhaeuser is operating from a strong financial position, and we are increasingly confident that the recent strength in U.S. housing will continue notwithstanding ongoing macroeconomic headwinds."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT